VALUE: analysis of results.

Suppr

超能文献

作者信息

Williams Simon G, Barker Diane, Schlosshan Dominik, Tan Lip-Bun

出版信息

Lancet. 2004;364(9438):932; author reply 935. doi: 10.1016/S0140-6736(04)17011-6.

DOI:10.1016/S0140-6736(04)17011-6

PMID:15364178

Abstract

摘要

相似文献

VALUE: analysis of results.

Lancet. 2004;364(9438):932; author reply 935. doi: 10.1016/S0140-6736(04)17011-6.

VALUE: analysis of results.

Lancet. 2004;364(9438):934-5; author reply 935. doi: 10.1016/S0140-6736(04)17015-3.

Valsartan treatment of hypertension--does VALUE add value?

Lancet. 2004 Jun 19;363(9426):2010-1. doi: 10.1016/S0140-6736(04)16484-2.

[Risk oriented therapy of hypertension. Lowering blood pressure and risk].

MMW Fortschr Med. 2007 Nov 15;149(46):53.

[The value of VALUE--a hypertension study which compared valsartan with amlodipine. New data support early, optimal blood pressure control for high-risk patients].

Lakartidningen. 2004 Jul 22;101(30-31):2426-7.

Two amlodipine/ARB combinations for hypertension.

Med Lett Drugs Ther. 2007 Dec 17;49(1276):101-2.

Valuable lessons from VALUE.

Blood Press. 2004;13(4):196-7. doi: 10.1080/080370504100000912.

Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.

Am J Hypertens. 2004 Jul;17(7):638-9; author reply 639-40. doi: 10.1016/j.amjhyper.2003.12.006.

VALUE: analysis of results.

Lancet. 2004;364(9438):931; author reply 935. doi: 10.1016/S0140-6736(04)17010-4.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

VALUE: analysis of results.

Lancet. 2004;364(9438):932; author reply 935. doi: 10.1016/S0140-6736(04)17011-6.

VALUE: analysis of results.

Lancet. 2004;364(9438):934-5; author reply 935. doi: 10.1016/S0140-6736(04)17015-3.

Valsartan treatment of hypertension--does VALUE add value?

Lancet. 2004 Jun 19;363(9426):2010-1. doi: 10.1016/S0140-6736(04)16484-2.

[Risk oriented therapy of hypertension. Lowering blood pressure and risk].

MMW Fortschr Med. 2007 Nov 15;149(46):53.

[The value of VALUE--a hypertension study which compared valsartan with amlodipine. New data support early, optimal blood pressure control for high-risk patients].

Lakartidningen. 2004 Jul 22;101(30-31):2426-7.

Two amlodipine/ARB combinations for hypertension.

Med Lett Drugs Ther. 2007 Dec 17;49(1276):101-2.

Valuable lessons from VALUE.

Blood Press. 2004;13(4):196-7. doi: 10.1080/080370504100000912.

Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.

Am J Hypertens. 2004 Jul;17(7):638-9; author reply 639-40. doi: 10.1016/j.amjhyper.2003.12.006.

VALUE: analysis of results.

Lancet. 2004;364(9438):931; author reply 935. doi: 10.1016/S0140-6736(04)17010-4.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9.